In a statement, Merck said an analysis of real-world data from an Israeli study, known as Clalit, showed that Lagevrio reduced hospitalisations and deaths due to COVID-19 in patients 65 years and ...

Merck has shipped around 6.4 million courses of Lagevrio around the world to date, showing strong demand outside the US, but is expecting sales of the drug going forward to be weaker than expected.

Sales of Merck's Covid antiviral pill, Lagevrio, also fell 40% to $383 million during the quarter. Still, that topped ...

The United Kingdom conditionally approved molnupiravir, branded as Lagevrio, earlier this month. Merck expects to produce 10 million courses of the treatment by the end of this year, with at least ...

and lower sales of COVID antiviral Lagevrio. Outside of China, Gardasil sales grew by double-digits in almost every major ...

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas ...

Merck reported adjusted earnings of $1.72 per ... Supply constraints in China also hurt sales. Sales of Lagevrio (molnupiravir) declined 37% to $121 million in the quarter.